Baloxavir Marboxil Patent Expiration
Baloxavir Marboxil is used for prevention and treatment of influenza. It was first introduced by Genentech Inc
Baloxavir Marboxil Patents
Given below is the list of patents protecting Baloxavir Marboxil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xofluza | US11925648 | Solid dosage form having excellent stability | Apr 21, 2041 | Genentech Inc |
| Xofluza | US12064438 | Pharmaceutical preparation excellent in light stability and dissolution property | Oct 09, 2039 | Genentech Inc |
| Xofluza | US11261198 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | Sep 25, 2038 | Genentech Inc |
| Xofluza | US10759814 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | Aug 09, 2037 | Genentech Inc |
| Xofluza | US11306106 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | Aug 09, 2037 | Genentech Inc |
| Xofluza | US10392406 | Substituted polycyclic pyridone derivatives and prodrugs thereof | Apr 27, 2036 | Genentech Inc |
| Xofluza | US10633397 | Substituted polycyclic pyridone derivatives and prodrugs thereof | Apr 27, 2036 | Genentech Inc |
| Xofluza | US8987441 | Substituted polycyclic carbamoyl pyridone derivative prodrug | Sep 21, 2031 | Genentech Inc |
| Xofluza | US8927710 | Substituted polycyclic carbamoylpyridone derivative | May 05, 2031 | Genentech Inc |
| Xofluza | US9815835 | Substituted polycyclic carbamolypyridone derivative | Jun 14, 2030 | Genentech Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Baloxavir Marboxil's patents.
Latest Legal Activities on Baloxavir Marboxil's Patents
Given below is the list recent legal activities going on the following patents of Baloxavir Marboxil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 12 Mar, 2024 | US11925648 |
| Patent eGrant Notification | 12 Mar, 2024 | US11925648 |
| Recordation of Patent eGrant | 12 Mar, 2024 | US11925648 |
| Recordation of Patent Grant Mailed Critical | 12 Mar, 2024 | US11925648 |
| Email Notification Critical | 12 Mar, 2024 | US11925648 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Mar, 2024 | US11925648 |
| Email Notification Critical | 22 Feb, 2024 | US11925648 |
| Issue Notification Mailed Critical | 21 Feb, 2024 | US11925648 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2024 | US10759814 |
| Dispatch to FDC | 08 Feb, 2024 | US11925648 |
Baloxavir Marboxil's Family Patents
